D14Ertd449e Inhibitors
Chemical inhibitors of D14Ertd449e encompass a range of compounds that primarily target cyclin-dependent kinases (CDKs), which are critical regulators of cell cycle progression. Alsterpaullone, for instance, is a chemical inhibitor that can disrupt the function of D14Ertd449e by targeting these kinases, leading to a cessation of their cell cycle control activities. Similarly, Roscovitine and Olomoucine are inhibitors that function by binding to CDKs, impeding their kinase activity, and as a result, can inhibit the function of D14Ertd449e. Purvalanol A, with its potent CDK-inhibiting ability, can also halt the cell cycle processes that D14Ertd449e is thought to influence. Indirubin-3'-monoxime, which is another selective inhibitor of CDKs, can impair cell cycle control mechanisms, leading to the functional inhibition of D14Ertd449e. The broad CDK inhibitor Flavopiridol can similarly inhibit D14Ertd449e by disrupting the cell cycle events it may affect. GW8510, which is more specific to CDK2, and Dinaciclib, which strongly inhibits several CDKs, both can lead to functional inhibition of D14Ertd449e by impairing cell cycle progression.
Additional chemical inhibitors include Kenpaullone, which, by hindering CDK activity, can inhibit the function of D14Ertd449e by interfering with cell cycle processes. SNS-032, known for its selectivity towards CDK2, CDK7, and CDK9, can also lead to the functional inhibition of D14Ertd449e by preventing both cell cycle and transcriptional regulation. AZD5438, which inhibits CDK1, CDK2, and CDK9, can similarly affect the functionality of D14Ertd449e by disrupting the control of the cell cycle and transcriptional processes. Lastly, Milciclib targets various CDKs for inhibition and, by doing so, can functionally inhibit D14Ertd449e by disrupting not only cell cycle regulation but also other cellular processes that involve CDK activity. Each of these inhibitors, through their interactions with CDKs, can inhibit the function of D14Ertd449e by altering the cell cycle pathways it is associated with.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). D14Ertd449e, involved in cell cycle regulation, can be functionally inhibited by this compound since CDKs are integral to cell cycle progression and the function of cell cycle-related proteins. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine serves as an inhibitor of CDKs. As D14Ertd449e functions within the realm of cell cycle progression, inhibition of CDKs by Roscovitine can lead to functional inhibition of D14Ertd449e due to the dependency of its activity on proper cell cycle control. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor. The activity of D14Ertd449e, which is likely contingent on CDK-regulated processes within the cell cycle, can be functionally inhibited by the prevention of CDK activity, thereby impeding the cell cycle-related functions in which D14Ertd449e is involved. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs. By inhibiting CDKs, Purvalanol A can disrupt the cell cycle processes and ultimately inhibit the function of D14Ertd449e, which is presumed to be associated with cell cycle regulation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a selective inhibitor of CDKs. By selectively inhibiting CDKs, Indirubin-3'-monoxime can impair the cell cycle control mechanisms, thereby functionally inhibiting D14Ertd449e if its activity is cell cycle-dependent. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs, which are pivotal in cell cycle regulation. Through the inhibition of these kinases, Flavopiridol can functionally inhibit the activity of D14Ertd449e by disrupting the cell cycle events that D14Ertd449e may influence. | ||||||
GW8510 | 222036-17-1 | sc-215122 sc-215122A | 1 mg 5 mg | $293.00 $626.00 | 8 | |
GW8510 acts as an inhibitor of CDK2. Since D14Ertd449e may participate in cell cycle-related pathways, the inhibition of CDK2 by GW8510 can lead to functional inhibition of D14Ertd449e due to the impairment of cell cycle progression. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a strong inhibitor of several CDKs. The inhibition of CDKs by Dinaciclib can lead to functional inhibition of D14Ertd449e by disrupting essential cell cycle-related functions that D14Ertd449e is presumed to be involved with. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is known to inhibit CDKs. By hindering CDK activity, Kenpaullone can inhibit the function of D14Ertd449e by interfering with the cell cycle processes that D14Ertd449e potentially regulates. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective CDK inhibitor, particularly of CDK2, CDK7, and CDK9. Inhibition of these kinases can lead to functional inhibition of D14Ertd449e by preventing the cell cycle and transcriptional regulation that D14Ertd449e might be involved in. | ||||||